Synaptogenix, Inc. (SNPX)

4.7100 -0.0700 (-1.46%) 市場開市。 截至 10:12AM EDT。

Synaptogenix, Inc.

1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
973 242 0005
https://www.synaptogen.com

版塊: Healthcare
行業: Biotechnology
全職員工: 5

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Alan J. Tuchman M.D., MBA(FAAN)	CEO & Director	303.35k	無	1947
Dr. Daniel L. Alkon M.D.	President, Chief Scientific Officer & Director	375k	無	1942
Mr. Robert Weinstein	CFO, Executive VP, Treasurer & Secretary	568.92k	無	1960

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

公司管治

截至 無 止，Synaptogenix, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。